FDA gives CorTec's brain implant a second breakthrough designation

CorTec announced on 31 August 2026 that the US Food and Drug Administration has granted its Brain Interchange system a second Breakthrough Device Designation. The new one covers communication: decoding intention so that a person with non-progressive quadriplegia, paralysis in all four limbs, can move a computer cursor by thought.

The first designation, granted in April 2026, covers stroke motor rehabilitation. Both apply to the same implant. As a therapeutic device it stimulates the brain to drive recovery; as an assistive one it decodes intention to restore control. CorTec says that places it among a small group of BCI companies holding more than one FDA breakthrough designation, and that it is the only one designated for stroke motor rehabilitation.

The company points to its ongoing stroke study at the University of Washington, where a participant used the same implant to control a computer through thought. That is one participant in a trial running for a different indication, not a result from the communication programme, which the designation now lets CorTec develop under structured FDA engagement.

A Breakthrough Device Designation is not a clearance or an approval. It grants priority review and closer contact with the agency, and the device still has to produce trial evidence for each indication it claims.